The company is partnering with Venusys Medical to provide training and hands-on workshops for local medical professionals in the growing Southeast Asian market.
Hugel Inc, a global medical aesthetics company, has launched its botulinum toxin product, Letybo, in Malaysia through a partnership with local distributor Venusys Medical Sdn Bhd.
The product was introduced at the Aesthetic Medicine & Surgery Conference & Exhibition (AMSC), Malaysia’s largest medical aesthetics conference. During the event, Konstantin Frank, a key opinion leader for Letybo in Europe, delivered a presentation on precise treatment outcomes of botulinum toxin procedures and shared clinical strategies to enhance results.
Following the conference, a brand launch event and hands-on workshop took place. The workshop provided a training program for approximately 100 local medical professionals, focusing on injection techniques that combine anatomical knowledge with clinical application.
“We will continue to offer customized training programs for local medical professionals in Malaysia through our strategic collaboration with Venusys Medical,” a statement attributed to a Hugel official says. “We aim to enhance the customer experience of our premium toxin brand and accelerate its market penetration to solidify our position in the region.”
Hugel holds regulatory approvals for its botulinum toxin products in over 65 countries, including the United States, China, and Europe. It was approved by the US Food and Drug Administration (FDA) in March 2024, making it the sixth neuromodulator to gain FDA approval.
Photo caption: Letybo
Photo credit: Hugel Inc
